35 results about "Adjuvant arthritis" patented technology

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p161nk4a and p21Cip1 in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Clip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.

The invention relates to chemical structure and a preparation method of a compound 2R-cardiospermin-5-p-hydroxybenzoate as well as an application of the compound in preparing medicines for treating rheumatoid arthritis. The 2R-cardiospermin-5-p-hydroxybenzoate, as a novel compound purified and prepared from a conventional traditional Chinese medicine, namely Sorbaria sorbifolia (L.) A. Brown, by the inventor, can be used for obviously inhibiting PEG2 and NO levels in serum of a mouse with adjuvant arthritis, and the compound is close to tripterygium glycosides at an equivalent dosage in activity; therefore, the compound can be used for preparing the medicines for treating and resisting the rheumatoid arthritis. The chemical structure and the preparation method of the compound as well as anti-RA (rheumatoid arthritis) activity of the compound are disclosed for the first time, therefore outstanding substantive features are guaranteed.

The invention relates to new medical application of cedrol (CE), in particular to new application thereof in preparing medicaments for relieving pain and treating arthritis. The cedrol is alpha-cedrolThe invention relates to new medical application of cedrol (CE), in particular to new application thereof in preparing medicaments for relieving pain and treating arthritis. The cedrol is alpha-cedrol, beta-CE or raceme of the two in any proportion, and the total effective dose of the cedrol is between 1 and 100 mg / kg / d. The CE is extracted from natural plants extensive in sources. The invention a, beta-CE or raceme of the two in any proportion, and the total effective dose of the cedrol is between 1 and 100 mg / kg / d. The CE is extracted from natural plants extensive in sources. The invention adopts rat-paw chondrus inflammation-inducing method and adjuvant arthritis to observe the anti-inflammatory effects of the CE, and results show that the CE has obvious effect of inhibiting nonspecificdopts rat-paw chondrus inflammation-inducing method and adjuvant arthritis to observe the anti-inflammatory effects of the CE, and results show that the CE has obvious effect of inhibiting nonspecific inflammation reaction caused by carrageenin and also has remarkable effect of treating and preventing the adjuvant arthritis. The invention adopts a tail-flick method to observe the analgesic effectsinflammation reaction caused by carrageenin and also has remarkable effect of treating and preventing the adjuvant arthritis. The invention adopts a tail-flick method to observe the analgesic effectsof the CE, and results show that the CE has remarkable analgesic effects on the light-heat stimulated tails of rats. The invention provides a raw material for anti-inflammatory and analgesic drugs, w of the CE, and results show that the CE has remarkable analgesic effects on the light-heat stimulated tails of rats. The invention provides a raw material for anti-inflammatory and analgesic drugs, which is exact in therapeutic effects, safe, convenient and extensive in sources, and can be combined with one or more pharmaceutically acceptable carriers so as to prepare a cedrol pharmaceutical comphich is exact in therapeutic effects, safe, convenient and extensive in sources, and can be combined with one or more pharmaceutically acceptable carriers so as to prepare a cedrol pharmaceutical composition or preparation.osition or preparation.

The invention provides application of an Aralia taibaiensis total saponin extract in preparing a medicine for treating arthritis. The invention also provides new application of Aralia taibaiensis saponin A. The medicine is used for treating adjuvant arthritis, osteoarthritis and gouty arthritis, and has definite drug effects. The medicine belongs to a pure natural preparation, does not treated by any organic solvent, and is safe and reliable; and the medicine has the advantages of low toxicity and no adverse effect after long-term usage, and has the actions of preventing and treating arthritis caused by various reasons.

The present invention relates to the chemical structure and preparation method of a compound 2S-cardiospermin-5-benzoate, and the application of the compound in the preparation of drugs for treating rheumatoid arthritis. 2S-cardiospermin-5-benzoate is a new compound purified and prepared by the applicant of the present invention from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. It can significantly inhibit the PEG in the serum of rats with adjuvant arthritis. 2 and NO level, and its activity is stronger than that of tripterygium glycosides in the same dose, and can be used to prepare medicines for treating rheumatoid arthritis. The chemical structure, preparation method and anti-RA activity of the compound are disclosed for the first time, so it has outstanding substantive features.

The invention relates to a chemical structure and preparing method of the compound 2S-cardiospermin-5-cis-p-coumarate and application of the compound to preparation of drugs for treating rheumatoid arthritis. 2S-cardiospermin-5-cis-p-coumarate is a novel compound prepared from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. through purification by the applicant of the invention. The compound can remarkably suppress the level of PEG2 and NO in serum of adjuvant arthritis rats. The activity of the compound is close to that of tripterygium glycosides of the same dose, and the compound can be used for preparing drugs for treating rheumatoid arthritis. The chemical structure, preparing method and anti-RA activity of the compound are disclosed for the first time, thus having prominent and substantive features.

The invention relates to the technical field of application of Nigella tumefica extract, and relates to the application of the extract of Nigella cumin in the preparation of adjuvant arthritis medicine. The present invention discloses for the first time the application of the flavonoids of Nigella tumosa, the volatile oil of Nigella tumosa and the composition of the flavonoids of Nigella tumosa and the volatile oil of Nigella tumosa as the preparation of adjuvant arthritis medicine. Experiments show that the flavonoids of Nigella tumosa, the volatile oil of Nigella tumosa and the composition of the flavonoids of Nigella cumulatus and the volatile oil of Nigella tumosa have a better therapeutic effect on adjuvant arthritis, and have obvious inhibitory effects on adjuvant arthritis. The role of immune function, it is particularly worth mentioning that the composition of Nigella tumefaction flavonoids and volatile oil of Nigella tumefaction has comparable therapeutic effects on adjuvant arthritis and dexamethasone on the disease.

The invention relates to a tumor necrosis factor receptor 1(TNFR1) blocking peptide and a TNFR1-Fc fusion protein formed by recombining the TNFR1 blocking peptide and a gene of an IgG1Fc segment. The TNFR1 blocking peptide is a 12-mer linear peptide. The invention also relates to a TNF binding cyclic peptide and a TNFR1 blocking cyclic peptide which are both cyclic 9 peptides (i.e. C7C), the TNFR1 blocking peptide, the TNFR1-Fc fusion protein, the TNF binding cyclic peptide, the TNFR1 blocking cyclic peptide and the like can competently inhibit the binding between the TNF-alpha and the TNFR1 no matter in vivo or vitro, thereby antagonizing the biological function of the TNF-alpha. And the TNFR1 blocking peptide, the TNFR1-Fc fusion protein, the TNF binding cyclic peptide, the TNFR1 blocking cyclic peptide and the like can obtain better treatment effects respectively on a rat model of adjuvant arthritis, a rat model of high fat and high glucose induced obesity and insulin-resistance and a rat model of trinitro-benzene-sulfonic acid (TNBS) induced experimental ulcerative colitis.